184 related articles for article (PubMed ID: 37827842)
1. First-in-Humans PET Imaging of
Li X; Ye J; Wang J; Quan Z; Li G; Ma W; Zhang M; Yang W; Wang J; Ma T; Kang F; Wang J
J Nucl Med; 2023 Dec; 64(12):1880-1888. PubMed ID: 37827842
[TBL] [Abstract][Full Text] [Related]
2. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
[TBL] [Abstract][Full Text] [Related]
3. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
[TBL] [Abstract][Full Text] [Related]
4. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
Parums DV
Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
[TBL] [Abstract][Full Text] [Related]
5. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
[TBL] [Abstract][Full Text] [Related]
6. Correlation between
Liu X; Wang SC; Ni M; Xie Q; Zhang YF; Lv WF; Geng GY
Abdom Radiol (NY); 2022 Apr; 47(4):1255-1264. PubMed ID: 35138462
[TBL] [Abstract][Full Text] [Related]
7. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
Lee A
Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
[TBL] [Abstract][Full Text] [Related]
8. Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer.
Kawada K; Toda K; Nakamoto Y; Iwamoto M; Hatano E; Chen F; Hasegawa S; Togashi K; Date H; Uemoto S; Sakai Y
J Nucl Med; 2015 Sep; 56(9):1322-7. PubMed ID: 26135109
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS
Hoshiyama H
Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617
[TBL] [Abstract][Full Text] [Related]
10. KRAS Inhibitor Resistance in
Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
[TBL] [Abstract][Full Text] [Related]
11. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients.
Lee SM; Bae SK; Jung SJ; Kim CK
Clin Nucl Med; 2015 Dec; 40(12):950-8. PubMed ID: 26359571
[TBL] [Abstract][Full Text] [Related]
12. Correlation between KRAS mutation and
Cho A; Jo K; Hwang SH; Lee N; Jung M; Yun M; Hwang HS
Abdom Radiol (NY); 2017 Jun; 42(6):1621-1626. PubMed ID: 28161825
[TBL] [Abstract][Full Text] [Related]
13. BCL-X
Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of F-18 FDG PET/CT for prediction of KRAS mutation in colorectal cancer patients: a systematic review and meta-analysis.
Kim SJ; Pak K; Kim K
Abdom Radiol (NY); 2019 May; 44(5):1703-1711. PubMed ID: 30603881
[TBL] [Abstract][Full Text] [Related]
15. Using tumor habitat-derived radiomic analysis during pretreatment
Zhao H; Su Y; Wang Y; Lyu Z; Xu P; Gu W; Tian L; Fu P
Cancer Imaging; 2024 Feb; 24(1):26. PubMed ID: 38342905
[TBL] [Abstract][Full Text] [Related]
16. Relationship between KRAS mutations and dual time point
Mao W; Zhou J; Zhang H; Qiu L; Tan H; Hu Y; Shi H
Abdom Radiol (NY); 2019 Jun; 44(6):2059-2066. PubMed ID: 30143816
[TBL] [Abstract][Full Text] [Related]
17. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
[TBL] [Abstract][Full Text] [Related]
18. Lack of association between KRAS mutations and 18F-FDG PET/CT in Caucasian metastatic colorectal cancer patients.
Krikelis D; Skoura E; Kotoula V; Rondogianni P; Pianou N; Samartzis A; Xanthakis I; Fountzilas G; Datseris IE
Anticancer Res; 2014 May; 34(5):2571-9. PubMed ID: 24778079
[TBL] [Abstract][Full Text] [Related]
19. Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.
Shiri I; Maleki H; Hajianfar G; Abdollahi H; Ashrafinia S; Hatt M; Zaidi H; Oveisi M; Rahmim A
Mol Imaging Biol; 2020 Aug; 22(4):1132-1148. PubMed ID: 32185618
[TBL] [Abstract][Full Text] [Related]
20. PET/CT Imaging of NSCLC with a α
Flechsig P; Lindner T; Loktev A; Roesch S; Mier W; Sauter M; Meister M; Herold-Mende C; Haberkorn U; Altmann A
Mol Imaging Biol; 2019 Oct; 21(5):973-983. PubMed ID: 30671741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
